Intra-Articular AAV9 α-L-Iduronidase Gene Replacement in the Canine Model of Mucopolysaccharidosis Type I

Figure 5

Synovial HS levels in the (a) high-dose +2 w, (b) high-dose +52 w, and (c) low-dose +52 w animals. Levels of synovial HS GAG at baseline (-6 weeks prior to AAV9 treatment) compared to levels at necropsy (+2- or +52-week post-AAV9 treatment). AAV9-IDUA joints are denoted in green, while AAV9-eGFP joints are denoted in red. The black dotted lines refer to synovial HS levels in age-matched normal dogs.

(a)

(b)

(c)